| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
5- and 6-desaturase gene expression by SREBP-1 and PPAR
Correspondence to: Hitoshi Shimano, To whom correspondence should be addressed., shimano-tky{at}umin.ac.jp (E-mail)
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
In the process of seeking sterol regulatory element-binding protein 1a (SREBP-1a) target genes, we identified and cloned a cDNA clone encoding mouse 5-desaturase (D5D). The hepatic expression of D5D as well as 6-desaturase (D6D) was highly activated in transgenic mice overexpressing nuclear SREBP-1a, -1c, and -2. Disruption of the SREBP-1 gene significantly reduced the expression of both desaturases in the livers of SREBP-1-deficient mice refed after fasting. The hepatic expression of both desaturases was downregulated by dietary PUFA, which were reported to suppress SREBP-1c gene expression. Sustained expression of hepatic nuclear SREBP-1c protein in the transgenic mice abolished the PUFA suppression of both desaturases. Although these data suggested that SREBP-1c regulates D5D and D6D expression, there was no difference in either the D5D or D6D mRNA level between fasted and refed normal mouse livers, indicating a mechanism for fasting induction of both desaturases. Administration of fibrate, a pharmacological ligand for peroxisome proliferator activating receptor (PPAR), caused a significant increase in expression of both desaturases.
The data suggested that D5D and D6D expression is dually regulated by SREBP-1c and PPAR, two reciprocal transcription factors for fatty acid metabolism, and could be involved in lipogenic gene regulation by producing PUFA. — Matsuzaka, T., H. Shimano, N. Yahagi, M. Amemiya-Kudo, T. Yoshikawa, A. H. Hasty, Y. Tamura, J-i. Osuga, H. Okazaki, Y. Iizuka, A. Takahashi, H. Sone, T. Gotoda, S. Ishibashi, and N. Yamada. Dual regulation of mouse 5- and 6-desaturase gene expression by SREBP-1 and PPAR. J. Lipid Res. 2002. 43: 107–114.
Supplementary key words: lipogenesis, nutrition, polyunsaturated fatty acids, sterol regulatory element-binding protein
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
PUFA such as arachidonic acid (AA, 20:4n-6), EPA (20:5n-3), and DHA (22:6n-3) play pivotal roles in a number of biological functions including brain development, cognition, reproduction, inflammatory responses, and hemostasis. In addition to being crucial components of membrane phospholipids and functioning in key steps of cell signaling, PUFA have a unique ability to suppress the transcription of hepatic genes encoding lipogenic enzymes (1) (2) (3) (4). The availability of 20- and 22-carbon (n-3 and n-6) PUFA is determined by the synthesis of 
-linolenic acid (18:3n-6) and stearidonic acid (18:4n-3) and by the subsequent elongation and desaturation of these fatty acids to 20:4n-6 and 22:6n-3 (5). One of two rate-limiting steps in the production of these polyunsaturated fatty acids is the desaturation of eicosatrienoic acid (20:3n-6) and eicosatetraenoic acid (20:4n-3) to 20:4n-6 and 20:5n-3, determined by the activity of 5-desaturase (D5D). The other step is the desaturation of linoleic acid (18:2n-6) and -linolenic acid (18:3n-3) to 18:3n-6 and 18:4n-3 catalyzed by 6-desaturase (D6D). Studies based on enzymatic activity suggest that the liver is the primary site for 20-carbon polyenoic fatty acid synthesis because the liver is an organ with a great amount of D6D and D5D activity (6). Both enzymes are coordinately regulated by various dietary conditions and hormonal levels in the liver. For instance, D6D activity is induced by peroxisome proliferators and by the supplementation of insulin to diabetic rats (7) (8). It is also highly suppressed by dietary PUFA, indicating that these enzymes are involved in feedback regulation in the production of AA, EPA, and DHA. Remarkable progress in understanding the molecular basis of the nutritional regulation of these desaturases has been made by cloning mammalian D5D and D6D cDNAs (9) (10). The predicted amino acid sequences were suggested to contain a cytochrome b5-like domain that might dispense with the presence of a separate cytochrome b5. Suppression of D5D and D6D activities by dietary unsaturated fatty acids was shown to be associated with decreased D5D and D6D mRNA levels (9) (10).
Sterol regulatory element-binding proteins (SREBP) are membrane-bound transcription factors that belong to the basic helix-loop-helix leucine zipper family (11) (12) (13). A sterol-regulated cleavage is required for SREBP to enter the nucleus and activate the transcription of genes involved in cholesterol and fatty acid synthesis by binding to a sterol regulatory element (SRE) or its related sequences, including E-boxes, within their promoter regions (14) (15). There are three forms of SREBP that have been characterized: SREBP-1a and -1c (also known as ADD1) and SREBP-2 (16) (17) (18). Most organs, including the liver and adipose tissue, express predominantly SREBP-2 and the c isoform of SREBP-1 (19). Lipogenic enzymes, which are involved in energy storage through the synthesis of fatty acids and triglycerides, are coordinately regulated at the transcriptional level during different metabolic states. In vivo studies demonstrated that SREBP-1c plays a crucial role in the dietary regulation of most hepatic lipogenic genes, whereas SREBP-2 is actively involved in the transcription of cholesterogenic enzymes. These include studies of the effects of the absence or overexpression of SREBP-1 on hepatic lipogenic gene expression (20) (21) (22), as well as physiological changes of SREBP-1c protein in normal mice after dietary manipulation, such as placement on high carbohydrate diets, polyunsaturated fatty acid-enriched diets, and fasting-refeeding regimens (23) (24) (25) (26) (27). Previous reports on the regulation of SREBP-1c have all demonstrated the induction to be at the mRNA level. Promoter analysis revealed that the expression of the SREBP-1c gene is regulated by two factors: SREBP itself, forming an autoloop, and the oxysterol liver X receptor-retinoid X receptor (28) (29). The mechanism for PUFA suppression of the SREBP-1c promoter is under investigation.
Both D5D and D6D play crucial roles in the production of PUFA, which in turn suppresses SREBP-1. In addition, D5D, D6D, and SREBP-1c are nutritionally regulated. These lines of evidence suggest that D5D and D6D expression might be related to SREBP-1 activity. In the screening of SREBP-activated genes, we cloned and identified a mouse D5D gene. Our current studies suggest that nutritional expression of D5D and D6D is regulated by both SREBP-1 and peroxisome proliferator activating receptor (PPAR).
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Materials and general methods
We purchased 20:3n-6 from Sigma (St. Louis, MO), Redivue [-32P]dCTP (6,000 Ci/mmol) from Amersham Pharmacia Biotech (Piscataway, NJ), and restriction enzymes from New England BioLabs (Beverly, MA).
Standard molecular biology techniques were used. DNA sequencing was performed with a CEQTM dye terminator cycle sequencing kit and CEQ2000 DNA analysis system (Beckman Coulter, Fullerton, CA).
Preparation of SREBP-1a transgenic liver cDNA library
An expression cDNA library of SREBP-1a transgenic liver (21) was prepared as previously described for construction of a cDNA library of SREBP-1-deficient mouse adipose tissue, except that poly(A)+ RNA was prepared from livers of SREBP-1a transgenic mice (29).
Cloning of mouse D5D cDNA
From a DNA microarray system using hepatic poly(A)+ RNA of SREBP-1a transgenic and nontransgenic littermate mice, we identified an expressed sequence tag (EST) clone (GenBank accession number AA068575) that was activated 8-fold in SREBP-1a transgenic liver as compared with wild-type liver, and resembled the mouse D6D. Using this sequence information, an [-32P]dCTP-labeled DNA probe was prepared and used in the screening from an SREBP-1a transgenic mouse liver cDNA library by colony hybridization. Positive clones were sequenced and the clones containing an open reading frame were used for expression experiments.
Expression of mouse D5D
HEK-293 cells were grown at 37°C in an atmosphere of 5% CO2 in DMEM containing 25 mM glucose, penicillin (100 U/ml), and streptomycin sulfate (100 µg/ml) supplemented with 10% FCS on 100-mm culture plates. At 80% confluence, the mouse D5D expression plasmid or the basic plasmid CMV7 alone (10 µg) was transfected into cells, using SuperFect transfection reagent (Qiagen, Valencia, CA) according to the manufacturer protocol. After transfection, cells were treated with either 100 µM 20:3n-6 diluted in ethanol or ethanol alone for 24 h and then used for fatty acid analysis.
Fatty acid analysis
Total fatty acid extracted from HEK-293 cells transfected with the mouse D5D expression plasmid or CMV7, in the presence of 100 µM 20:3n-6, was analyzed by gas chromatography of methyl ester derivatives. Lipids were extracted and transmethylated with methanolic HCl, and the fatty acid methyl esters were analyzed as described previously (10).
Animal experiments
All mice were housed in a controlled environment with a 12-h light/dark cycle and free access to water and diet. For fatty acid or drug experiments, 7-week-old male C57BL/6J mice (21–23 g) were purchased from CLEA (Tokyo, Japan) and adapted to the environment for 1 week. Before sacrifice, each group of animals was fed a diet containing the indicated fatty acids and drugs for 7 days. Fasting and refeeding regimens for wild-type and SREBP-1 knockout mice were previously described (22). Transgenic mice overexpressing the nuclear form of SREBP-1a, -1c, and -2 in the liver under the control of the phosphoenolpyruvate carboxykinase promoter were previously described (21) (30) (31). SREBP-1c and -2 transgenic mice were homozygous for the transgene (32). These three transgenic lines and wild-type controls (nontransgenic littermates of SREBP-1a transgenic mice) were put on a high protein/low carbohydrate diet to induce transgenic mice for 2 weeks, and were fasted for 12 h before sacrifice. For fasting and refeeding treatment, SREBP-1-deficient and wild-type mice were fasted for 24 h and fed a high sucrose/fat-free diet for 12 h.
Total RNA preparation and Northern blotting
Total RNA was extracted from mouse livers and various tissues with TRIzol reagent (Life Technologies, Rockville, MD). RNA samples were run on a 1% agarose gel containing formaldehyde and transferred a nylon membrane (Hybond-N; Amersham Pharmacia Biotech). The probes used were labeled with [-32P]dCTP, using the Megaprime DNA labeling system kit (Amersham Pharmacia Biotech). The cDNA probe for mouse D5D was prepared by digesting the cloned cDNA with NotI and EcoRI. The cDNA probes for mouse D6D and ribosomal phosphoprotein P0 (36B4) were prepared as described previously (10) (22). The membranes were hybridized with the radiolabeled probe in Rapid-Hyb buffer (Amersham Pharmacia Biotech) at 65°C and washed in 0.1x SSC, 0.1% SDS at 65°C. The resulting bands were quantified by exposure of the filters to BAS2000 with BASstation software (Fuji Photo Film, Tokyo, Japan).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Cloning mouse D5D as an SREBP-activated gene
DNA microarray analysis identified an EST clone whose expression was increased 7-fold in the livers of SREBP-1a transgenic as compared with wild-type mice. This clone (GenBank accession number AA068575) was originally named an EST clone slightly similar to mouse D6D in the database. Mouse D6D was cloned and reported (10). The sequences suggested that this clone should encode something similar, but not identical, to D6D. Using this EST clone as a probe, we cloned the cDNA clone that contains an open reading frame (ORF) from an SREBP-1a transgenic liver cDNA library. The DNA sequence analysis revealed that the predicted amino acid sequence was highly similar to human and rat D5D (9). Alignment of the predicted amino acid sequences for mouse and human D5D is shown in Fig 1. Eighty-eight percent of the amino acid sequence for the mouse and human homologs was identical. The high homology includes the presence of a cytochrome b5 domain, transmembrane domains, and histidine-rich regions, all of which were reported for human D5D and mouse D6D.
|
Expression of mouse D5D
The high similarity of the predicted amino acid sequence from the ORF of the cloned mouse cDNA to the human D5D amino acid sequence suggested that the cDNA encodes the mouse D5D. To confirm this, the cDNA was expressed in HEK-293 cells supplemented with C20:3n-6. As shown in Table 1, gas chromatography analysis of the cellular fatty acids revealed that overexpression of this putative D5D clone increased the relative amounts of C20:4n-6 and C22:4n-6, accompanying a decrease in C20:3n-6 in the cells as compared with mock-transfected cells. The data suggested that the cells transfected with the cDNA were capable of synthesizing 20:3n-6 from eicosadienoic acid (20:2n-6), indicating that the cDNA product has a D5D activity.
|
Tissue distribution of mouse D5D mRNA
Expression of D5D and D6D was examined in various tissues as estimated by Northern blot analysis. Mouse D5D is a single transcript that is approximately 4.5 kb in size ( Fig 2). The expression was high in the adrenal gland, liver, brain, and testis, tissues where lipogenesis and steroidogenesis are active. The tissue distribution pattern of mouse D6D expression was similar, suggesting that D5D and D6D cooperatively produce polyenoic fatty acids.
|
Activation of D5D and D6D expression in liver of SREBP transgenic mice
We performed Northern blot analysis of liver RNA from nuclear SREBP-1a, -1c, and -2 transgenic and wild-type mice to estimate the effects of nuclear SREBP on the expression of D5D as well as D6D. As shown in Fig 3, the hepatic mRNA level of D5D was robustly increased by overexpression of nuclear SREBP-1a, -1c, and -2 at this order of magnitude. Hepatic D6D mRNA levels were also induced by SREBP overexpression in a pattern similar to that of D5D mRNA. A shorter mouse D6D transcript was barely detectable from livers of fasted wild-type mice, but became prominent in SREBP transgenic livers. This minor, short transcript was identified in human D6D and was reported to be nutritionally regulated as well as the major transcript. The data indicate that every isoform of SREBP can activate the expression of both desaturase genes.
|
Nutritional regulation of D5D and D6D expression in SREBP-1-deficient mice
Nutritional regulation of hepatic D5D and D6D mRNA levels was estimated in wild-type and SREBP-1 deficient mice. As shown in Fig 4, these mice were fasted and then refed with a high sucrose/fat-free diet. Interestingly, the wild-type mice did not show a marked change in D5D or D6D mRNA level between fasting and refeeding. In the fasted state, the SREBP-1-deficient mice showed hepatic expression levels of both D5D and D6D similar to those of wild-type mice. After refeeding, there was a considerable reduction in the expression of both desaturases in SREBP-1 null mice, showing a much lower level than in the refed wild-type mice. Expression of PPAR was induced by fasting and suppressed by refeeding, whereas the SREBP-1c mRNA level showed the opposite response. These data demonstrate that the hepatic expression of D5D and D6D is not upregulated by refeeding, but that SREBP-1 contributes strongly to their expression in the refed state. The nutritional regulation of these enzymes is distinct from that of regular lipogenic enzymes, which are suppressed by fasting and are markedly induced by refeeding, although both these desaturases and lipogenic enzymes are regulated by SREBP-1.
|
Effects of PUFAs on D5D and D6D expression
Numerous dietary studies indicate that the hepatic activity and expression of both desaturases are induced by diets low in essential fatty acids and suppressed by diets rich in PUFA such as vegetable or marine oils. We compared mouse hepatic D5D and D6D expression levels in mice fed a fat-free high carbohydrate diet with various kinds of fatty acids. Fig 5 showed that stearate (C18:0) or oleate (C18:1) did not affect the expression of D5D and D6D. However, when a high carbohydrate diet was supplemented with linoleate or EPA, the expression of both desaturases was considerably suppressed, and the reduction was more marked with fish oils rich in EPA and DHA. These data were consistent with previous reports on the expression of human and rat desaturase genes. We also tested PUFA suppression of their expression in SREBP-1c transgenic mice ( Fig 6). This line of transgenic mice expresses amounts of nuclear SREBP-1c protein, derived from the transgene, similar to the physiological level of nuclear SREBP-1c in the livers of normal refed mice (27). The sustained level of nuclear SREBP-1c completely abolished PUFA suppression of D5D and D6D mRNA levels. These data suggest that endogenous SREBP-1c could be involved in maintaining D5D and D6D expression in a fed state.
|
|
Effects of PPAR ligands on D5D and D6D expression
As shown in Fig 4, fasting treatment induces expression of PPAR, crucial for fatty acid oxidation. To estimate the possible involvement of PPAR in D5D and D6D expression, we challenged mice with fibrate, a pharmacological PPAR ligand. Addition of fibrate to the diet increased both D5D and D6D mRNA levels ( Fig 7) whereas troglitazone, which induces PPAR, had no effect, indicating that both desaturases can be induced by PPAR and not by PPAR. These results are consistent with the previous report that peroxisome proliferators enhanced linoleic acid metabolism in rat liver (8).
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
D5D and D6D as potential SREBP-1 targets
The current study clearly demonstrates that SREBP activate the expression of both D5D and D6D in the liver. Both hepatic D5D and D6D mRNA levels were markedly increased by overexpression of SREBP, with preference for SREBP-1 relative to SREBP-2. Furthermore, the absence of SREBP-1 markedly impaired the hepatic expression of these desaturases in a refed state. All these data suggest that D5D and D6D are highly potential SREBP target genes and that SREBP-1 plays a pivotal role in the hepatic expression of these desaturases, at least under lipogenic conditions. The physiological relevance of SREBP activation of these desaturases is currently unknown. Under lipogenic conditions, when SREBP-1 is activated, newly synthesized fatty acids could be dominated by saturated or monounsaturated fatty acids, and availability of essential fatty acids might be limited. In this situation, activation of D5D and D6D might be necessary to meet cellular requirements for AA, EPA, and DHA. Cumulative evidence suggests that the cellular availability of PUFA is crucial for the regulation of lipogenesis. On the assumption that the PUFA that these desaturases synthesize can be used for inhibition of lipogenesis, SREBP-1 induction of these desaturases would contribute to efficient suppression of lipogenesis whenever essential fatty acids such as C18:2n-6 become available. It is consistent with the previous report that D6D activity is important for PUFA suppression of hepatic lipogenic gene expression. This is the first observation that there could be a feedback system for the hepatic SREBP-1c-lipogenesis system, which was thought to depend essentially on the supply of carbohydrates as discussed in the autoloop activation of the SREBP-1c promoter underlying the overshooting phenomenon in a refed state (28).
A mechanism for the feedback suppression of D5D and D6D by PUFA
Dietary PUFA have been reported to decrease both the activity and expression of D5D and D6D (9) (10), a finding supported by our current observations. PUFA were reported to inhibit SREBP-1 activity by multiple mechanisms (24) (25) (26) (27) (33) (34). Considering our new finding that D5D and D6D are potential SREBP targets, it is likely that downregulation of D5D and D6D expression by PUFA could be mediated through suppression of SREBP-1. This hypothesis is further supported by the observation that PUFA suppression of D5D and D6D was completely abolished by the sustained amount of nuclear SREBP-1c protein forcibly expressed in SREBP-1c transgenic mice.
Dual regulation of D5D and D6D expression by SREBP-1 and PPAR
This unique fashion of nutritional regulation (activation by SREBP-1c, but no change by a fasting-refeeding treatment) places D5D and D6D in a position distinct from regular lipogenic enzymes. In particular, in SREBP-1 knockout mice, D5D and D6D mRNA levels are considerably higher in fasted liver than in refed liver. These observations can be explained by the hypothesis that, in addition to SREBP-1c-mediated induction as observed in the refed state of normal mice, there is another regulatory mechanism that activates the expression of D5D and D6D in a fasted state. Our results from administration of fenofibrate, a PPAR ligand, indicate that PPAR is responsible for the fasting induction of these desaturases. Furthermore, we and others previously reported that starvation increases the expression of PPAR, which should enhance fasting-induced activation of D5D and D6D in addition to the ligand activation of PPAR (27) (35). In a fasted state, lipolysis from adipose tissue is enhanced and circulating free fatty acids enter the liver for ß-oxidation that is controlled by PPAR. Many of these free fatty acids are essential fatty acids, and can be both ligands for both PPAR and substrates for D5D and D6D. Activation of D5D and D6D by PPAR in the liver might be important to produce required amounts of PUFA.
Taken together, the expression of D5D and D6D could be regulated by two distinct mechanisms, one through SREBP-1c as is shown by its induction during refeeding, and the other through PPAR that is inducible by fasting. Dual regulation of D5D and D6D by the two factors SREBP-1 and PPAR, which possess opposing activation properties depending on nutritional status, caused no remarkable change in the overall expression of these enzymes between fasting and refeeding as schematized in Fig 8. This dual regulation of both desaturases contributes to a stable production of PUFA that are essential for cellular functions regardless of energy state.
|
Further analysis of the promoter regions of the D5D and D6D genes will be required. Interestingly, these genes are located close to each other in an inverted orientation, sharing an 11-kb upstream region (9). It would be intriguing if D5D and D6D shared in this region enhancers that are important for nutritional regulation, such as an SRE responsible for SREBP activation and/or a peroxisome proliferator response element, which could explain PPAR ligand activation. The current study suggests that PUFA play an essential role in energy metabolism by regulating or modifying these lipid transcription factors and that D5D and D6D could be involved in this system by producing PUFA.
|
ACKNOWLEDGMENTS |
|---|
This study was supported by the Organization for Pharmaceutical Safety and Research (OPSR, Promotion of Fundamental Studies in Health Science), and by Health Sciences Research grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare, Japan.
Manuscript received June 1, 2001; and in revised form October 8, 2001
Abbreviations:
AA, arachidonic acid; D5D, 5-desaturase; D6D, 6-desaturase; PPAR, peroxisome proliferator activating receptor; SRE, sterol regulatory element; SREBP, sterol regulatory element-binding protein
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
-5 desaturase. J. Biol. Chem. 274:37335-37339-6 desaturase. J. Biol. Chem. 274:471-477
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Igarashi, K. Ma, L. Chang, J. M. Bell, and S. I. Rapoport Rat heart cannot synthesize docosahexaenoic acid from circulating {alpha}-linolenic acid because it lacks elongase-2 J. Lipid Res., August 1, 2008; 49(8): 1735 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Holness Leptin: A Central Role in an Expanding Answer to Weight Loss Endocrinology, December 1, 2007; 148(12): 5601 - 5603. [Full Text] [PDF]
|
|
|
|
|
|
N. Gallardo, E. Bonzon-Kulichenko, T. Fernandez-Agullo, E. Molto, S. Gomez-Alonso, P. Blanco, J. M. Carrascosa, M. Ros, and A. Andres Tissue-Specific Effects of Central Leptin on the Expression of Genes Involved in Lipid Metabolism in Liver and White Adipose Tissue Endocrinology, December 1, 2007; 148(12): 5604 - 5610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Igarashi, K. Ma, L. Chang, J. M. Bell, and S. I. Rapoport Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain J. Lipid Res., November 1, 2007; 48(11): 2463 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Saether, T. N Tran, H. Rootwelt, H. J Grav, B. O Christophersen, and T. B Haugen Essential fatty acid deficiency induces fatty acid desaturase expression in rat epididymis, but not in testis Reproduction, February 1, 2007; 133(2): 467 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, D. Botolin, J. Xu, B. Christian, E. Mitchell, B. Jayaprakasam, M. Nair, J. M. Peters, J. Busik, L. K. Olson, et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity J. Lipid Res., September 1, 2006; 47(9): 2028 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rodriguez-Cruz, A. R. Tovar, B. Palacios-Gonzalez, M. del Prado, and N. Torres Synthesis of long-chain polyunsaturated fatty acids in lactating mammary gland: role of {Delta}5 and {Delta}6 desaturases, SREBP-1, PPAR{alpha}, and PGC-1 J. Lipid Res., March 1, 2006; 47(3): 553 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Song, L. Zhu, C. M. Picardo, G. Maguire, V. Leung, P. W. Connelly, and D. S. Ng Coordinated alteration of hepatic gene expression in fatty acid and triglyceride synthesis in LCAT-null mice is associated with altered PUFA metabolism Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E17 - E25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, T. Y. Nara, and M. T. Nakamura Peroxisome proliferator-activated receptor {alpha} is required for feedback regulation of highly unsaturated fatty acid synthesis J. Lipid Res., November 1, 2005; 46(11): 2432 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Jump, D. Botolin, Y. Wang, J. Xu, B. Christian, and O. Demeure Fatty Acid Regulation of Hepatic Gene Transcription J. Nutr., November 1, 2005; 135(11): 2503 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-E. O. Jordal, B. E. Torstensen, S. Tsoi, D. R. Tocher, S. P. Lall, and S. E. Douglas Dietary Rapeseed Oil Affects the Expression of Genes Involved in Hepatic Lipid Metabolism in Atlantic Salmon (Salmo salar L.) J. Nutr., October 1, 2005; 135(10): 2355 - 2361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Tovar, I. Torre-Villalvazo, M. Ochoa, A. L. Elias, V. Ortiz, C. A. Aguilar-Salinas, and N. Torres Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats J. Lipid Res., September 1, 2005; 46(9): 1823 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cheon, T. Y. Nara, M. R. Band, J. E. Beever, M. A. Wallig, and M. T. Nakamura Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPAR{alpha} in nonproliferating species Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1525 - R1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, D. Botolin, B. Christian, J. Busik, J. Xu, and D. B. Jump Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases J. Lipid Res., April 1, 2005; 46(4): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Sandberg, M. Bloksgaard, D. Duran-Sandoval, C. Duval, B. Staels, and S. Mandrup The Gene Encoding Acyl-CoA-binding Protein Is Subject to Metabolic Regulation by Both Sterol Regulatory Element-binding Protein and Peroxisome Proliferator-activated Receptor {alpha} in Hepatocytes J. Biol. Chem., February 18, 2005; 280(7): 5258 - 5266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ide Interaction of Fish Oil and Conjugated Linoleic Acid in Affecting Hepatic Activity of Lipogenic Enzymes and Gene Expression in Liver and Adipose Tissue Diabetes |
